CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working. CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.

CARVYKTI®
CARE PARTNER CHECKLIST

A Quick Reference for Providing Support During Treatment

What is CARVYKTI®?

- CARVYKTI® is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working
- CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI®?

CARVYKTI® may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

- fever (100.4°F/38°C or higher)
- chills or shaking chills
- fast or irregular heartbeat
- difficulty breathing
- very low blood pressure
- dizziness/lightheadedness
- effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
  - — feeling confused, less alert, or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing, and understanding words, memory loss
  - — loss of coordination affecting movement and balance, slower movements, changes in handwriting
  - — personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
  - — tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
  - — facial numbness, difficulty moving muscles of face and eyes

It is important that you tell your healthcare providers that you have received CARVYKTI® and to show them your CARVYKTI® Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

Please read full Important Safety Information. Please read full Prescribing Information, including Boxed Warning and read the Medication Guide. Discuss any questions you have with your healthcare team.

CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV Infusion

A CARE PARTNER'S JOURNEY WITH CARVYKTI® (ciltacabtagene autoleucel)

As a care partner, you're taking on many responsibilities, but you don't have to bear them all alone. Part of being a great care partner is knowing how and when to involve others. Delegating even the smallest tasks frees you to do more urgent and pressing things for the person you are supporting.

Having the right tools and support can help pave the way for a positive experience when caring for someone going through the CARVYKTI® treatment process. This checklist covers some of the ways you can help them navigate through this treatment journey.

This quick reference is designed to assist you as a care partner, along with any other care partners, to be prepared to support someone undergoing treatment with CARVYKTI®. This checklist is divided into 3 time periods to help you understand your unique role in each part of this process.



Between cell collection and pre-infusion treatment, the doctor may prescribe additional therapy to treat multiple myeloma, often called bridging therapy.*

*208/208 patients in the CARTITUDE-4 study received bridging therapy.

IMPORTANT SAFETY INFORMATION

In a study comparing CARVYKTI® to standard therapy, there was a higher rate of death in the first 10 months in the CARVYKTI® arm (14%) compared to the standard therapy arm (12%). The increased rate of deaths occurred before receiving CARVYKTI® and after treatment with CARVYKTI®. The reasons for death were progression of multiple myeloma and side effects of the treatment.

Please read full Important Safety Information. Please read full Prescribing Information, including Boxed Warning and read the Medication Guide. Discuss any questions you have with your healthcare team.

CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV Infusion

BEFORE TREATMENT

Here are some actionable steps you can take to provide valuable support to someone who is about to start treatment after being prescribed CARVYKTI® (ciltacabtagene autoleucel) by their healthcare provider.

Check the boxes below to help you remember what has been completed!

☐ **Help plan for the overall CARVYKTI® treatment process**

- Review patient educational materials available on www.carvykti.com with the person you care for to understand the treatment process
- If you haven't already, consider signing up to receive more information as you go through the process at www.carvykti.com/sign-up-for-updates
- Ensure appointments are scheduled and coordinated with the healthcare team

☐ **Help build a financial plan**

- Review insurance coverage and assess the costs associated with the treatment
- Make sure all necessary paperwork is completed regarding payments, coverage, and any financial considerations related to the treatment journey

☐ **Learn more about the MyCARVYKTI® Patient Support Program**

- The MyCARVYKTI® Patient Support Program, sponsored by Janssen Biotech, Inc., and Legend Biotech, is designed to help eligible patients prescribed CARVYKTI® and their care partners with support during treatment
  - — Patients who meet financial and other eligibility requirements, and their caregivers, may receive assistance with transportation, lodging, and out-of-pocket costs related to meals and other travel expenses associated with treatment at the Certified Treatment Center
  - — Support from MyCARVYKTI® Patient Support Specialists, who are available to help guide eligible patients through the enrollment process and assist with program benefits
- To learn more about MyCARVYKTI® and find out if the patient is eligible, call 1-800-559-7875, Monday–Friday, 8:00 AM–8:00 PM ET

☐ **Collect proper documentation and information about the person you are caring for**

- Check with the Certified Treatment Center to determine what documentation is needed. Information may include the patient's phone number, emergency contacts, insurance cards, and a government-issued ID

BEFORE TREATMENT (CONT'D)

- [ ] **Arrange for travel and lodging near the Certified Treatment Center (if needed)**
  - Plan transportation (eg, air, ground) and lodging (if needed) to a Certified Treatment Center for cell collection appointment
  - Research lodging options for a longer-term stay near the Certified Treatment Center (pre-infusion treatment through at least 4 weeks post treatment monitoring period)

- [ ] **Make sure the patient has packed for an extended stay if travel to a Certified Treatment Center is required**
  - Help patient pack and prepare for at least a 4-week stay away from home
  - Prepare for your own travel and stay as the care partner
  - Coordinate caregiving schedule and responsibilities if multiple care partners will be involved

- [ ] **Ensure the patient has a comfortable homecoming environment after treatment**
  - Ensure the patient's living space is clean, comfortable, and safe
  - Proactively stock up on essential supplies such as personal care items, comfortable clothing, and entertainment items such as movies, books, games, or puzzles

- [ ] **Explore local support programs**
  - Coordinate with family, friends, or online groups that can offer assistance and emotional support throughout the treatment and recovery phases
  - Connect with local support programs in the area and explore the patient education and support groups section of the CARVYKTI® website (www.carvykti.com)

TREATMENT

The treatment process generally takes about 2 to 3 months to complete. The person you are caring for will have appointments for cell collection, pre-infusion, and treatment. Being prepared for them can help alleviate stress. Consider these supportive actions for the person you are caring for as they start their CARVYKTI® (ciltacabtagene autoleucel) treatment:

CELL COLLECTION

- [ ] **Help get the patient to the cell collection appointment on time**
  - Make sure to pack the essentials needed for the appointment (and travel if required)
  - Travel with the patient to the Certified Treatment Center and ensure timely arrival

- [ ] **Support the patient during the ~3- to 6-hour cell collection appointment**
  - Have yourself or another care partner accompany the patient to the appointment
  - Stay present during the appointment, providing emotional support and comfort

- [ ] **Ask the healthcare team about next steps**
  - Understand subsequent steps and what to do between collection and infusion
  - Confirm how the Certified Treatment Center will communicate scheduling of pre-infusion and infusion appointments

PRE-INFUSION AND ONE-TIME CARVYKTI® INFUSION TREATMENT

- [ ] **Schedule pre-infusion and treatment appointments based on the process and communications from the Certified Treatment Center**
  - Stay connected with the treatment center during the time between cell collection and infusion
  - Schedule appointments and confirm transportation/lodging logistics when directed

- [ ] **Plan transportation to/from appointment**
  - Ensure patient is able to get to the multiple pre-infusion treatment appointments
  - Travel with the patient to the Certified Treatment Center and ensure timely arrival
  - Finalize nearby lodging for pre-infusion treatment through the approximately 4-week post treatment monitoring period

TREATMENT (CONT'D)

- [ ] **Help the person you are caring for with logistics for staying at the Certified Treatment Center**
  - Pack essentials for the Certified Treatment Center stay during and after infusion
  - Create a schedule in advance for check-ins/care support from all care partners involved

- [ ] **Support the person you are caring for, physically and emotionally**
  - Accompany the patient to all their appointments
  - Stay present during treatment, providing emotional support and comfort

- [ ] **Communicate with the doctors and healthcare team**
  - Advocate for the needs and wants of the person you are caring for
  - Ask questions about treatment, potential side effects, and what to expect during the recovery

- [ ] **Make sure all important health information is handy**
  - Take notes on instructions and tips from the healthcare team
  - Monitor for any symptoms and report changes in the patient's condition

For information on what to expect during treatment, visit www.carvykti.com/resources-and-support to view the *CARVYKTI® Patient Milestone Guidebook* resource.

AFTER TREATMENT

The individual you are caring for will stay at the Certified Treatment Center where the treatment was administered for at least 10 days after CARVYKTI® (ciltacabtagene autoleucel) infusion. During this time, they will be monitored by their healthcare team. They should plan to stay close to the location where they received treatment for at least 4 weeks. Visit www.carvykti.com/resources-and-support to view the *CARVYKTI® Post-Infusion Monitoring Guide.*

WHILE PATIENT IS STAYING AT THE CERTIFIED TREATMENT CENTER
(~10 DAYS POST INFUSION)

☐ **Check in daily**

- Visit the patient daily to see how they are doing from a physical and emotional standpoint and look for signs and symptoms of any side effects. You should notify the healthcare team as soon as you see one

☐ **Report signs and symptoms of side effects**

- Contact the healthcare team if there are any observed signs and symptoms of side effects to ensure proper care is provided immediately
- Visit www.carvykti.com/resources-and-support to view the *CARVYKTI® Monitoring for Potential Side Effects* resource

☐ **Provide overall support**

- Ensure the person you are caring for eats and stays hydrated
- Offer emotional support to help them feel better during and after treatment

For more information on long-term care and monitoring, visit www.carvykti.com/resources-and-support to view the *CARVYKTI® Post-Infusion Monitoring Guide*.

AFTER TREATMENT (CONT'D)

WHILE THE PATIENT IS STAYING NEAR THE CERTIFIED TREATMENT CENTER

(AT LEAST 4 WEEKS AFTER THE 10-DAY POST-INFUSION CERTIFIED TREATMENT CENTER STAY)

☐ **Work out Certified Treatment Center discharge logistics**

- Plan for patient discharge from the Certified Treatment Center and confirm lodging for the patient near the Certified Treatment Center in accordance with Certified Treatment Center guidelines
- Help transport patient from the Certified Treatment Center to lodging (or home if within guidelines)

☐ **Help with daily needs for the patient**

- Ensure meals and other daily needs of the patient are provided
- Help make sure that the patient refrains from driving or hazardous activities for at least 8 weeks following treatment

☐ **Monitor for signs and symptoms of side effects**

- Contact the healthcare team if there are any observed side effects to ensure proper care is provided immediately

☐ **Help arrange follow-up appointments as required by the Certified Treatment Center**

- Ensure the patient is able to get to each follow-up appointment
- Travel with them to the appointment and ensure timely arrival

Take care of your own needs as well

Carve out time specifically for resting and doing things you enjoy. It's easy to get so immersed in caring for someone that you neglect your own physical, mental, and emotional health.

AFTER TREATMENT (CONT'D)

☐ **Help to arrange transportation home**

- Coordinate transportation home for the patient (and care partners)
- Move patient out of temporary lodging

☐ **Communicate with the Certified Treatment Center and primary oncology healthcare team**

- Understand the plan for long-term monitoring and any follow-ups requested by the Certified Treatment Center's healthcare team
- Update the patient's other healthcare providers on treatment progress and any developments

For more information on long-term care and monitoring, visit www.carvykti.com/resources-and-support to view the *CARVYKTI® Post-Infusion Monitoring Guide*.

IMPORTANT SAFETY INFORMATION

What is CARVYKTI® (ciltacabtagene autoleucel)?

- CARVYKTI® is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working
- CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI®?

CARVYKTI® may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

- fever (100.4°F/38°C or higher)
- chills or shaking chills
- fast or irregular heartbeat
- difficulty breathing
- very low blood pressure
- dizziness/lightheadedness
- effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
  - feeling confused, less alert, or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing, and understanding words, memory loss
  - loss of coordination affecting movement and balance, slower movements, changes in handwriting
  - personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
  - tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
  - facial numbness, difficulty moving muscles of face and eyes

It is important that you tell your healthcare providers that you have received CARVYKTI® and to show them your CARVYKTI® Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

Before you receive CARVYKTI® tell your healthcare provider about all your medical conditions, including if you have:

- Current or past neurologic problems (such as seizures, stroke, new or worsening memory loss)
- Lung or breathing problems
- Heart problems
- Liver problems
- Kidney problems
- A recent or active infection
- Low blood counts

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

IMPORTANT SAFETY INFORMATION (CONT'D)

How will I receive CARVYKTI®?

- CARVYKTI® is made from your own white blood cells, so your blood will be collected by a process called 'leukapheresis' (loo-kah-fur-ee-sis). The procedure can take 3 to 6 hours and may need to be repeated.
- Your white blood cells are sent to a manufacturing center to make CARVYKTI®. It takes about 4-5 weeks from the time your cells are received at the manufacturing site and are available to be shipped back to your healthcare provider, but the time may vary.
- While CARVYKTI® is being made, you may get other medicines to treat the multiple myeloma. This is so that your multiple myeloma does not get worse.

Before you get CARVYKTI®, your healthcare provider will give you chemotherapy for 3 days to prepare your body.

30 to 60 minutes before you are given CARVYKTI®, you may be given other medicines. These may include:

- medicines for an allergic reaction (antihistamines)
- medicines for fever (such as acetaminophen)

When your CARVYKTI® is ready, your healthcare provider will give CARVYKTI® to you through a catheter (tube) placed into your vein (intravenous infusion). Your dose of CARVYKTI® will be given in one infusion bag. The infusion usually takes approximately 30-60 minutes.

After getting CARVYKTI®, you will be monitored at the certified healthcare facility where you received your treatment for at least 10 days after the infusion.

You should plan to stay close to the location where you received your treatment for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.

What should I avoid after receiving CARVYKTI®?

- Do not drive, or operate heavy machinery, or do other activities that could be dangerous if you are not mentally alert, for at least 8 weeks after you get CARVYKTI®. This is because the treatment can cause memory and coordination problems, sleepiness, confusion, dizziness, seizures, or other neurologic side effects as discussed by your healthcare provider.
- You must not be given certain vaccines called live vaccines for some time before and after CARVYKTI® treatment. Talk to your healthcare provider if you need to have any vaccinations.
- Do not donate blood, organs, tissues, or cells for transplantation.

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible or reasonably likely side effects of CARVYKTI®?

The most common side effects of CARVYKTI® include:

- fever (100.4°F/38°C or higher), chills
- dizziness or light-headedness
- headache, muscle or joint pain, feeling very tired
- altered mental state, confusion
- infections
- low levels of antibodies (immunoglobulins) in the blood
- cough, being short of breath
- diarrhea, nausea, decreased appetite, constipation
- fast or irregular heartbeat
- problems with blood clotting

In a study comparing CARVYKTI® to standard therapy, there was a higher rate of death in the first 10 months in the CARVYKTI® arm (14%) compared to the standard therapy arm (12%). The increased rate of deaths occurred before receiving CARVYKTI® and after treatment with CARVYKTI®. The reasons for death were progression of multiple myeloma and side effects of the treatment.

CARVYKTI® can cause a very common side effect called cytokine release syndrome or CRS, which can be severe or fatal. Symptoms of CRS include fever, difficulty breathing, dizziness or lightheadedness, nausea, headache, fast heartbeat, low blood pressure, or fatigue. Tell your healthcare provider right away if you develop fever or any of these other symptoms after receiving CARVYKTI®.

CARVYKTI® can increase the risk of life-threatening infections including COVID-19 that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

CARVYKTI® can cause various neurologic side effects, some of which may be severe or fatal. Symptoms include but are not limited to confusion, disorientation, loss of consciousness, seizures, difficulty speaking, reading or writing, tremor, slower movements, changes in personality, depression, tingling and numbness of hands and feet, leg and arm weakness, and facial numbness.

CARVYKTI® can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets [cells that help blood to clot]), which may make you feel weak or tired, or increase your risk of severe infection or bleeding that may lead to death. After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection, are feeling tired, or have bruising or bleeding.

IMPORTANT SAFETY INFORMATION (CONT'D)

CARVYKTI® may increase your risk of getting cancers including certain types of blood cancers. Your healthcare provider should monitor you for this.

Having CARVYKTI® in your blood may cause some commercial Human Immunodeficiency Virus (HIV) tests to incorrectly give you an HIV-positive result even though you may be HIV-negative.
These are not all the possible side effects of CARVYKTI®. Call your healthcare provider if you have any side effects.

You may report side effects to FDA at 1-800-FDA-1088.

Please read full Prescribing Information, including Boxed Warning, for CARVYKTI®.

cp-258861v6

Johnson&Johnson

LEGEND BIOTECH